💨 Abstract

Twenty-seven states sued 23andMe to prevent the sale of personal genetic data to a biotech company, Regeneron Pharmaceuticals, without customer consent. This move comes amidst the company's bankruptcy and planned $256 million acquisition by Regeneron. The states argued that genetic information is too sensitive to be sold without explicit consent, while 23andMe customers use the service for ancestry and health research. Regeneron maintains it will follow privacy policies and applicable laws.

Courtesy: WTOP Staff